Flerie

A3P Biomedical has developed Stockholm3, a blood-based diagnostic test that helps to determine the risk of developing aggressive prostate cancer in a more specific and sensitive manner than today’s standard of care, PSA.

Flerie invested in A3P Biomedical in 2022 and has since been an active owner supporting the company’s commercialisation process. During 2024, A3P Biomedical announced the launch of Stockholm3 through partnerships in the US, Switzerland and Germany.

“After contributing as active owners during the initial stage of A3P Biomedical’s commercial development we believe now is the right time to divest our holding in the company. It is clear that A3P Biomedical has a great future ahead, but this opportunity will allow us to prioritise our core focus areas, namely development of therapeutics and pharma services. This naturally aligns with our strategy to continuously optimise the structure of our investment portfolio, while also providing our companies with the best opportunities for long-term success,” comments Ted Fjällman, CEO of Flerie.

Prior to the divestment, Flerie’s ownership in A3P Biomedical amounted to 8% and the holding was 1.1% of Flerie’s Net Asset Value.